US patent office declines to review two Ampyra patents; the FDA expands indication for Promacta; the Biosimilars Council argues against CMS proposal for biosimilar coding
Novartis appeals the ban on its biosimilar Zarxio; AbbVie petitions for distinct biosimilar labels; Sanofi will study Toujeo in a real-world setting
Bristol-Myers Squibb's Opdivo serves up lukewarm lung-cancer results; new cancer drugs are too expensive, Sloan Kettering oncologist tells ASCO attendees; Teva settlement could stymie industry use of pay-for-delay patent tactics
Worldwide spending on cancer medications hit $100 billion last year; Bayer adds an anticoagulant to its pipeline for $100 million; GlaxoSmithKline has a new chairman
Hedge fund activist challenges Shire patents; CMS issues documents on biosimilars; Astellas Pharma and the University of Texas MD Anderson Cancer Center partner on leukemia treatment
A Florida Congressman introduced a bill that would expand patent protections; Novo Nordisk expects to increase diabetes medication prices; AbbVie expanded its Alzheimer's research
J&J loses another Risperdal case; Pfizer slashes jobs at research center; Actavis challenges ulcerative colitis drug's patent.
A New Jersey District Court ruled that the Pulmicort Respules patent is invalid, opening the door for Actavis to launch a generic version of the billion-dollar asthma drug.
BMS loses breakthrough therapy status, Gilead's pricing comes under fire in Europe, and pharma fights Italy's off-label Avastin use.
Pfizer said the $17-billion decision to acquire Hospira will not affect the timeline of its divide-or-stay-whole decision.
A survey showed patients are not really clear on what causes cancer.
CEO Ian Read told investors the company has cash to make a deal, but there is no urgent need.
Amgen sues Sanofi and Regeneron over PCSK9 patents; FDA panel wants Chantix black box to stay; Valeant-Allergan uproar rises in pitch; Pharmacyclics and Roche team up against CLL; and GSK's Ebola vax may "miss" the current crisis.
A draft guidance publication date determines whether drugmakers get three or five years of market exclusivity.
NY's attorney general alleges that a formulation switch is an attempt to create monopoly.
J&J subsidiary Janssen has abandoned its patent lawsuit over the anti-seizure medication topiramate, which is part of Vivus's prescription weight-loss drug Qsymia.
The Japanese drugmaker is looking to add as much as a year onto the patent life of some of its drugs after the DEA dragged out their scheduling decisions.
The regulator and patients will chat for two days in October.
The generic ED pills sell for five cents less than Pfizer's branded blue pill, but the undercutting is a bit deeper.
The WSJ reports that Merck, Sanofi and GSK are looking to put older medications at arm's length.
Novartis and Sun agreed generic Gleevec won't surface until February 2016.
A London court knocked down two Roche/Genentech patents, making a clearer path for biosimilars of the breast cancer drug. The primary patent lapses in July.
A court granted Lilly six more years of patent protection for the almost $3-billion-dollar-a-year cancer drug.
A study by consulting firm Accenture shows that patients not only expect digital outreach, but that their desire to be engaged is consistently being ignored.
The company is suing Torrent Pharmaceuticals, which wants to market a drug before the patent lapses in 2019.
Analysts indicate the earlier-than-expected patent loss will not be a significant upset to Pfizer's present. The drugmaker plans to appeal the decision.
India's Ranbaxy logged yet another recall, while the country's stance on patent protection keeps the industry on edge.
The White House's proposed FY 2015 budget gives an additional 1% to the FDA.
Higher prices helped insulate Q4 and annual sales, which fell and rose 2%, respectively. Lilly said its insulin glargine biosimilar will go nowhere if it is not substantially different from the competition.
PMLive has documents that outline a strategy to keep intellectual property laws from relaxing in South Africa.
Content marketing is not advertising in the old sense. In its use of social media, content marketing challenges consumers while relying on their input. It is proactive and responsive to their concerns, needs and energy. Content marketing has become the new voice of marketing. Learn what you need to know and how pharma marketers can adapt to this innovative venture into social media by clicking here for access.